Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.11%), DAX (0.08%), CAC +0.07%

Sep 30 ,2025

  • Synopsis

    • European equity markets are set to open mixed amid Asian equities advancing Tuesday. Semis driving outperformance of Taiwan's benchmark. Mainland China markets extending gains ahead of Golden Week break while Hong Kong off highs. Japan, South Korean and Australian indexes flat. S&P 500 futures unchanged afterhours. JGB curve bull flattening while Treasuries little changed. Australian yields moving lower ahead of RBA meeting. Dollar strengthening against Korean won, steady elsewhere. Crude extending pullback on weekend OPEC+ production hike reports. Gold advancing to fresh record high. Bitcoin unchanged after rebounding to one-week high.

    • In central banks, Bank of Finland's conf on monetary policy sees Governor Rehn speech at 11:30CET, BOE's Lombardelli and Riksbank's Thedéen panelists at 13:50 and ECB Lagarde speech at 14:50. BOE's Cleland panellist at 9:00CET and Bundesbank's Balz panellist at 11:30 at SIBOS 2025. ECB's Machado speech at 12:15CET at S&P Global Ratings 2025 European Financial Institutions Conf whilst ECB's Elderson is a panelist at 15:00CET at event 'Climate action that works for you - An agenda for competitiveness, prosperity and resilience'. BOE Mann fireside chat at 14:25BST at FT's Future of Financial Intelligence conf 'Geopolitical landscape context' and BOE Breeden speech at 16:30BST at Cardiff Business School title The Monetary Policy Outlook. Bundesbank's Nagel in conversation at 19:00CET with author David Marsh at German Embassy London.

    • In politics, Germany's Federal Cabinet begin a 2-day retreat with Chancellor to make press statement before and after the retreat. EU Competitiveness Council (Research) meets and EU Commission will host the third Our Baltic conf in Stockholm. Norway's energy minister Aasland among the participants in IEA's high-level roundtable on strengthening energy infrastructure resilience. In the UK, there's GCA Annual Conf (food retail industry). Also, North American - EU Agriculture Conf (through Thu), EU's Hansen speech on Wed.

    • Macroeconomic releases include: Germany Sep unemployment change, preliminary CPI, Aug retail sales, France Sep preliminary CPI, Aug PPI, consumer spending, Italy Sep preliminary CPI, Aug PPI, UK Q2 final GDP, Sep shop price index - BRC, Switzerland Sep leading indicators - KOF, Sweden Aug retail sales, Denmark Q2 final GDP, Austria Aug PPI, Greece Aug PPI, Jul retail sales, Ireland Sep preliminary HICP, Portugal Sep preliminary CPI

    • In corporate news, Hornbach Holding (HBH.GR) reported Q2 earnings and issued FY guidance. Emeis SA (EMEIS.FP) released H1 earnings and confirmed FY25 targets. Lhyfe (LHYFE.FP) and Addex Therapeutics (ADXN.SW) are also out with H1/Q2 earnings. In the UK, Close Brothers (CBG.LN), A.G. BARR (BAG.LN), BOKU (BOKU.LN), Card Factory (CARD.LN), Next 15 Group (NFG.LN) are expected to update the market with their latest numbers. On M&A front, TotalEnergies (TTE.FP) reportedly may sell part of stake in Adani Green Energy, according to Bloomberg. Elsewhere, Celyad Oncology (CYAD.BB) announced research facility divestiture.

  • Politics/Macro/World News

    • How Brussels seeks to bypass Orbán's block on Ukraine's EU bid - FT

    • Trump imposes 10% tariff on timber, lumber; 25% tariff on kitchen cabinets - release

    • Trump secures Netanyahu's agreement to Gaza deal but Hamas support in question - Reuters

    • UK Sep shop price index +1.4% y/y vs consensus +1.2% and prior +0.9% - BRC

  • Top company news

    • Earnings/updates

      • ADXN.SW (Addex Therapeutics) -- reports Q2 net loss from cont. ops. (CHF2M) vs year-ago (CHF1.5M)

      • SIGHT.FP (GenSight Biologics) -- reports H1 net income (€7.0M) vs year-ago (€5.8M)

      • HBH.GR (Hornbach Holding) -- reports Q2 EPS €4.12 vs year-ago €4.82

      • B8FK.GR (Biofrontera AG) -- reports H1 EBITDA €2.1M vs year-ago (€3.6M); reaffirms FY revenue guidance €17M-20M

      • SOL.SM (Soltec Power Holdings) -- reports H1 net income (€21.8M) vs year-ago (€125.9M)

      • LHYFE.FP (Lhyfe) -- reports H1 Net Income (€21.7M) vs year-ago (€14.0M)

      • EMEIS.FP (Emeis SA) -- reports H1 net income (€137M) vs year-ago (€257M)

    • M&A

      • TTE.FP (TotalEnergies) -- may sell part of stake in Adani Green Energy - Bloomberg

      • CYAD.BB (Celyad Oncology) -- announces research facility divestiture

      • ROVI.SM (Laboratorios Farmaceuticos Rovi, S.A.) -- ROVI announces acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA).

      • ELLAKTOR.GA (Ellaktor) -- announces financial close of previously announced sale of Aktor Concessions

    • Healthcare

      • ROG.SW (Roche Holding) -- Roche announces primary results from the TSIX Study Program

      • EKTA.B.SS (Elekta) -- announces use of its MRI adaptive radiation therapy platform, Unity, is associated with improved quality of life among men with localized prostate cancer

      • VLA.FP (Valneva) -- reports 95% seroresponse four years after single shot of Chikungunya vaccine IXCHIQ

      • NANO.FP (Nanobiotix) -- presents updated phase 1 results continuing to support JNJ-1900 (NBTXR3) plus anti-pd-1 as a potential new 1L or 2L+ option in anti-pd-1 Navee or resistant R/m-hnscc at ASTRO 2025

      • ORX.SS (Orexo) -- US awarded $8M by BARDA for OX390 development partnership

    • Other

      • UBSG.SW (UBS Group) -- and Switzerland may reach compromise on capital rules - Reuters

      • REP.SM (Repsol) -- achieves first oil at Leon-Castile

      • BNR.GR (Brenntag) -- appoints Bjørn Andersen as COO

      • FGR.FP (Eiffage) -- awarded >€1.5B contract for three substations for Bretagne Sud, Narbonnaise Sud-Hérault and Golfe de Fos French offshore wind farms

      • HIAB.FH (Hiab) -- distributes additional dividend of €1.56; dividend payment day will be 9-Oct-25

      • AKER.NO (Aker ASA) -- initiates a buyback program of up to ~429K of its own shares

  • Key rating changes

    • Upgrades

      • BC.IM (Brunello Cucinelli) -- to outperform from market perform at Bernstein

      • CFEB.BB (Cie d'Entreprises CFE) -- to outperform from neutral at Oddo

      • PUM.GR (Puma) -- to neutral from underperform at BNP Paribas Exane

    • Downgrades

      • VALMT.FH (Valmet) -- to hold from buy at Danske Bank

      • INDT.SS (Indutrade) -- to hold from buy at Pareto

      • RBI.AV (Raiffeisen Bank International) -- to equal weight from overweight at Barclays

  • Data

    • Nikkei +0.08% to 45077.99

    • Hang Seng +0.08% to 26643.53

    • Shanghai Composite +0.52% to 3882.64

    • S&P futures (4.3) vs prior close of 6713.5

    • €-$ +0.0004 or +0.04% to 1.1732

    • $-¥ (0.32) or (0.21%) to 148.28

    • €-¥ (0.31) or (0.18%) to 173.94

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE